On January 27, Shanghai Kaikai Industry Company Limited(600272) released the 2021 annual report, which kicked off the disclosure of the annual report of Shanghai stock market. In 2021, Shanghai Kaikai Industry Company Limited(600272) achieved an operating revenue of 670 million yuan, a year-on-year decrease of 12.08%, and the net profit attributable to the owner of the parent company was 21.7172 million yuan, a year-on-year increase of 58.81%. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 4.0343 million yuan, with a year-on-year increase of 89.54%.
Shanghai Kaikai Industry Company Limited(600272) said that the pharmaceutical sector of the company was greatly affected by the medical reform policy. In the face of the continuous promotion of national drug volume procurement, the implementation of the new regional GPO and the cancellation of the long prescription policy for chronic diseases, the operating income of Rexi pharmaceutical circulation business decreased. Lexi actively took countermeasures to adjust the sales structure and reduce the sales proportion of low-yield products. At the same time, in order to comprehensively promote the healthy transformation, the company adjusted the two main businesses of the company and carried out comprehensive reform of the clothing sector from April 2021. Most of the company’s net profit in 2021 comes from non operating profit and loss, mainly due to the special subsidy of 10 million yuan for the comprehensive reform project of the clothing sector and 2.9 million yuan for the revitalization of time-honored brands.
In addition, Shanghai Kaikai Industry Company Limited(600272) plans to distribute profits based on the total share capital registered on the date of equity distribution, and distribute cash dividends of RMB 0.27 (including tax) to all shareholders for every 10 shares, with a total dividend of RMB 6.561 million.
